priors.science/reviews/targeted-therapy-breast-cancer

Targeted Therapy Breast Cancer

The current evidence on 8 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

8claims tracked
146primary papers reviewed
4 Jun 2026latest evidence review
Weeklyre-scored against new papers
4 Established · 4 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableCDK4/6 inhibitors plus endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancerCdk46Established90%20
StableOlaparib or talazoparib in BRCA-mutant breast cancerBrca DnaEstablished89%20
StablePembrolizumab neoadjuvant therapy in triple-negative breast cancerIci BCEstablished87%16
StableCapivasertib (AKT inhibitor) in hormone receptor-positive metastatic breast cancerPi3k AktEstablished85%20
StableAlpelisib in PIK3CA-mutant hormone receptor-positive metastatic breast cancerPi3k AktLikely84%20
StableAbemaciclib adjuvant therapy in early breast cancerCdk46Likely83%17
StableSacituzumab in third-line triple-negative breast cancerBrca DnaLikely83%20
StablePembrolizumab in PD-L1-positive metastatic triple-negative breast cancerIci BCLikely81%19
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic